Vitiligo
Vitiligo is far more than a cosmetic skin problem. It is an acquired, complex autoimmune disease in which functioning melanocytes in the epidermis are selectively destroyed. At the molecular level, vitiligo results from an interplay between oxidative stress inside the cells and an immune response driven by CD8+ T cells.
The process begins when melanocytes are damaged by a build-up of reactive oxygen species (ROS), which disrupts the endoplasmic reticulum. This stress causes melanocytes to release danger signals (DAMPs) and chemokines such as CXCL9 and CXCL10. These chemokines bind CXCR3 receptors on cytotoxic CD8+ T cells and draw them into the basal layer. There, the T cells release interferon-gamma (IFN-gamma), which switches on the JAK-STAT (Janus kinase–signal transducer and activator of transcription) pathway in nearby keratinocytes. The result is a self-perpetuating immune amplification loop that kills melanocytes through apoptosis (programmed cell death).
At Haute-Derma, we see vitiligo as a breakdown of immune tolerance that exhausts the melanocyte population. Our core goal is not just to treat the white patches, but to halt active autoimmunity and reawaken the dormant melanocyte stem cells (MSCs) in the hair follicle bulge. Rather than treating symptoms alone, we follow a strategy of targeted immune stabilization combined with activation of these microscopic stem cell reservoirs to restore skin color as durably as possible.
Our Specialist Approach to Managing Vitiligo at Haute-Derma
Because vitiligo is constantly changing, Haute-Derma follows strict treatment principles:
- Separating active and stable phases: Treatment must be tailored to disease activity. We avoid invasive procedures or aggressive repigmentation stimulation until the immune response has been brought under control.
- Harnessing hair follicle stem cells: Natural repigmentation depends largely on MSCs maturing and migrating out of the outer root sheath of the hair follicle. Preserving the follicles in affected skin is therefore key to success.
- Screening for associated autoimmune disease: Vitiligo is closely linked to other systemic autoimmune disorders, especially thyroid disease.
Assessment and Disease Staging at Haute-Derma
To build a safe treatment plan, our assessment follows these steps:
- Wood’s lamp examination: Under Wood’s light (peak wavelength 365 nm), vitiligo patches glow a chalky, milk-white color with very sharp borders because epidermal pigment is completely absent. It also helps detect early patches that are not yet visible to the naked eye.
- Dermoscopic assessment of disease activity: Microscopic signs help determine precisely whether the disease is active or stable.
- Active phase: Blurred, serrated borders with fine confetti-like depigmented dots; three-color (trichrome) lesions; dilated vessels around follicles; early white hairs (leukotrichia).
- Stable phase: Sharp borders with perilesional hyperpigmentation; a uniform milk-white color that is not spreading; normal vessel pattern; hairs may keep their pigment or turn white only late.
- Biomarker and immunology tests: Thyroid antibodies (anti-TPO, anti-TG), thyroid function (FT3, FT4, TSH) and antinuclear antibodies (ANA) are checked to rule out polyglandular autoimmune syndromes.
Clinical Management and Cosmetic Treatment at Haute-Derma
Depending on the type and stage of disease, Haute-Derma combines advanced technology with standardized treatment protocols.
- Halting the Immune Attack (Active Phase)
- Topical Janus kinase (JAK) inhibitors: New targeted agents such as ruxolitinib or tofacitinib. These small molecules penetrate the epidermis and directly block JAK1/JAK2, interrupting IFN-gamma signaling. This shuts down production of CXCL9/CXCL10, stops CD8+ T cells from attacking melanocytes and allows the epidermis to recover.
- Oral mini-pulse (OMP) corticosteroid therapy: For rapidly progressive, widespread vitiligo, low-dose dexamethasone is given on two consecutive days each week to calm the systemic immune storm without causing prolonged adrenal suppression.
- Stimulating Repigmentation (Stable Phase)
- Targeted 308 nm excimer laser: A focused beam of monochromatic 308 nm light is applied to the depigmented skin. This wavelength stimulates MSCs in the outer root sheath to mature and migrate into the surrounding skin, creating dot-like islands of color around follicles (perifollicular repigmentation), while also triggering apoptosis of cytotoxic T cells in the area.
- Whole-body narrowband UVB (311 nm): For extensive disease (more than 15–20% of body surface area), given 2–3 times a week to keep the immune system stable and stimulate repigmentation over large areas.
- Advanced Surgical Options (Treatment-Resistant Patches)
- Non-cultured epidermal cell suspension (NCES) grafting: For segmental or localized vitiligo that has been completely stable for more than 12 months but has not responded to phototherapy. The doctor takes a thin skin sample from the thigh or buttock and separates the cells with trypsin to obtain a suspension of fresh melanocytes and keratinocytes. The vitiligo patch is then finely resurfaced with an Er:YAG laser to create a recipient bed, and the cell suspension is sprayed or applied onto it. This technique can achieve even repigmentation of more than 80% in many patients without leaving a cobblestone scar.
